



NIH Scientific Management Review Board



# Translational Medicine and Therapeutics Working Group

September 14, 2010

---

---

---

---

**Arthur Rubenstein, M.B.B.Ch.**  
Executive Vice President of the University of  
Pennsylvania for Health System and Dean of the  
University of Pennsylvania School of Medicine

# TMAT Working Group Charge

- **Identify the attributes, activities, and functional capabilities of an effective translational medicine program for advancing therapeutics development; and**
- **Broadly assess, from a high-level view, the NIH landscape for extant programs, networks, and centers for inclusion in this network and recommend their optimal organization**

# TMAT Working Group Roster

## Non-Federal

- Arthur Rubenstein, MBBCh (*Chair*)
- William Brody, MD, PhD
- Gail Cassell, PhD
- William Roper MD, MPH
- Solomon Snyder, MD
- Huda Zoghbi, MD
- Norman Augustine (*ad hoc*)

## Federal

- Josephine Briggs, MD
- Anthony Fauci, MD
- Stephen Katz, MD, PhD
- Griffin Rodgers, MD  
MACP
- Susan B. Shurin, MD
- Harold Varmus, MD
- Francis Collins, MD, PhD  
(*ex officio*)

# TMAT Working Group Considerations

- **The Working Group will consider how the Agency could leverage and organize a wide range of existing NIH resources and effectively implement the Cures Acceleration Network**
- **In addressing its charge, the Working Group will consider:**
  - **Current NIH-supported infrastructure, initiatives, and resources with direct relevance to the therapeutics development pipeline**
  - **Methods to synergize, and avoid competition with, resources in the private sector**

# TMAT Working Group Considerations *(cont)*

- **In addressing its charge, the Working Group will consider:**
  - **Prior recommendations for strengthening the clinical and translational research enterprise at NIH, including recommendations of the IOM, and relevant lessons learned from industry, academia, non-profit organizations, etc.; and**
  - **Metrics and methodologies that could be used for evaluating the impact of changes in the organization and management of the therapeutics development program**

# TMAT Working Group Deliverables

- **The Working Group's report to the full board will include:**
  - **Description of attributes, activities, and associated functional capabilities of a translational medicine program optimized to enhance therapeutics development;**
  - **Recommendations for organizing the Agency's existing components to optimize a translational medicine and therapeutics program; and**
  - **Metrics for evaluating successes and any untoward consequences of organizational and/or management changes, in particular consequences for the progress of research in areas affected by the proposed changes.**

# TMAT Consultation: Agenda Overview

- **Session I**
  - **New Paradigm Opportunities for Translational Medicine and Therapeutics Discovery: Establishing A Role for NIH**
- **Session II**
  - **Bridging the Gap: Defining and Understanding the Necessary NIH Capabilities and Infrastructure**
- **Session III**
  - **Cultivating Partnerships: Setting Goals and Defining Success**
- **Session IV**
  - **Engaging in a Dialogue with the Public**